Home Featured Page 3

Featured

Latest

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Book Club! Built To Burn: Tales of the Desert Carnies of Burning Man

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Bridging Worlds: Psychedelics, Community, and the Work of Our Time

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

1 234...299 Page 3 of 299

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Book Club – Trip Sitting

Book Club! Built To Burn: Tales of the Desert Carnies of Burning Man

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Bridging Worlds: Psychedelics, Community, and the Work of Our Time

Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back...

Matt Xavier -The Psychedelic DJ

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

EDITOR PICKS

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY